The world leader in serving science
|
|
Type
|
Public |
---|---|
Traded as | NYSE: TMO S&P 500 Component |
Industry | Laboratory equipment |
Founded | 2006 by merger of Thermo Electron and Fisher Scientific |
Headquarters | Waltham, Massachusetts, USA |
Key people
|
Marc N. Casper (President & CEO) Joe Beery (CIO) |
Products | Analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics |
Revenue | $18.27 billion (2016) |
Net income
|
$2.45 billion (2016) |
Number of employees
|
65,000 (2017) |
Website | www.thermofisher.com |
Thermo Fisher Scientific is an American multinational biotechnology product development company, created in 2006 by the merger of Thermo Electron and Fisher Scientific. In April 2013, after a competitive bidding with Hoffmann-La Roche, Thermo Fisher acquired Life Technologies Corp for $13.6 billion in a deal that would rank the firm as one of the leading companies in the genetic testing and precision laboratory equipment markets.
Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos is a MIT PhD in mechanical engineering and Nomikos a Harvard Business School graduate. It focused on providing analytical and laboratory products and services, and had revenues of over $2 billion in 2004.
Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh. It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education.
On May 14, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific. On November 9, 2006, the companies announced that the merger had been completed. However, the Federal Trade Commission ruled that this acquisition was anticompetitive with regard to centrifugal evaporators, requiring Fisher to divest Genevac. In April 2007, Genevac was sold to Riverlake Partners LLC and the merger closed with FTC approval.
Currently, the company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Chromacol, Nalgene, Cellomics, Pierce Protein Research and Fermentas). According to company figures, 46% of its sales are in life sciences, 20% in healthcare, and 34% in industrial/environmental and safety.
Thermo Fisher has offices and operations in many countries, notably the U.S. and in Europe.
In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand in testing for allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash purchase.
In 2013 Thermo Fisher agreed to buy Life Technologies for $13.6 billion. The sale was completed on 4 February 2014, and the Life Technologies brand became part of the Life Sciences Solutions Group of Thermo Fisher Scientific.
In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs, manufactures and delivers technologies used in bioprocessing solutions. In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million from Johnson Matthey, and the acquisition was completed at the end of September
In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research.
In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction was completed a day later. In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. In May, the company announced it would acquire CDMO, Patheon, for $7.2 billion.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Scientific Materials Co.
(Est 1902)
Scientific Supplies, Ltd
(Acq 1925)
Eimer & Amend
(Acq 1940)
E. Machlett & Sons
(Acq 1957)
Janssen Chimica
Eastman Kodak Company
(Organic Chemicals div)
Apogent Technologies Inc.
(Acq 2004)
Acquire Athena Diagnostics
(Acq 2006)
Kendro Laboratory Products
(Acq 2005)
Rupprecht and Patashnick Co., Inc.
(Acq 2005)
NITON LLC
(Acq 2005)
InnaPhase Corporation
(Acq 2004)
US Counseling Services, Inc.
(Acq 2004)
Jouan SA
(Acq 2004)
Laboratory Management Systems, Inc.
(Acq 2003)
Phadia
(Acq 2011)
Caltag Laboratories
Zymed
CellzDirect
BioSource
InforMax
Panvera
Dynal
Molecular Probes
Ethrog Biotechnology
Research Genetics, Inc
(Acq 1999)
NOVEX
Applied Biosystems
(Merged 2008)
Advanced Scientifics
(Acq 2015)
Alfa Aesar
(Acq 2015)
Genetic MicroSystems
(Acq 1999)
Neomorphic
(Acq 2000)
ParAllele Bioscience
USB Corporation
(Acq 2008)
Panomics
(Acq 2008)
True Materials
(Acq 2000)
eBioscience
(Acq 2012)
FEI Company
(Est 1971 as Field Electron and Ion Co. Merged 1997)
Philips Electron Optics
(Merged 1997)
Micrion
(Acq 1999)
MTI-GlobalStem
(Acq 2016)
Finesse Solutions, Inc.
(Acq 2017)
Core Informatics
(Acq 2017)
MOVA
(Acq 2004)
Banner Pharmacaps
(Acq 2013)
Royal DSM NV
(Pharmaceutical div, merged 2014)
Gallus Pharmaceuticals
(Acq 2014)
Agere Pharmaceuticals
(Acq 2015)
Source:
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-10-25 | Future report Set alerts | |
Q2 2022 | 2022-07-28 | 5.51 | 5.51 |
Q1 2022 | 2022-04-28 | 7.25 | 7.25 |
Q4 2021 | 2022-02-02 | 6.54 | 6.54 |
Q3 2021 | 2021-10-27 | 5.76 | 5.76 |
Q2 2021 | 2021-07-28 | 5.60 | 5.60 |
Q1 2021 | 2021-04-29 | 7.21 | 7.21 |
Q4 2020 | 2021-02-01 | 7.09 | 7.09 |
Q3 2020 | 2020-10-21 | 5.63 | 5.63 |
Q2 2020 | 2020-07-22 | 3.89 | 3.89 |
2016-07-06 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | |
2016-05-29 | Reiterated Rating | Leerink Swann | Buy | |
2016-05-27 | Boost Price Target | Mizuho | Buy | $166.00 to $170.00 |
2016-05-27 | Reiterated Rating | BTIG Research | Neutral | |
2016-05-19 | Reiterated Rating | Morgan Stanley | Buy | |
2016-05-19 | Reiterated Rating | Mizuho | Buy | $163.00 to $166.00 |
2016-05-11 | Reiterated Rating | Bank of America | Buy | $163.00 |
2016-05-11 | Reiterated Rating | Bank of America Corp. | Buy | $163.00 |
2016-05-03 | Reiterated Rating | Mizuho | Buy | $160.00 to $163.00 |
2016-04-30 | Reiterated Rating | Morgan Stanley | Buy | |
2016-04-30 | Reiterated Rating | Leerink Swann | Buy | |
2016-04-29 | Downgrade | Jefferies Group | Buy to Hold | |
2016-04-04 | Boost Price Target | Mizuho | Buy | $150.00 to $160.00 |
2016-03-23 | Boost Price Target | Goldman Sachs | $156.00 | |
2016-03-23 | Boost Price Target | Goldman Sachs Group Inc. | $156.00 | |
2016-03-21 | Reiterated Rating | Leerink Swann | Outperform | |
2016-03-21 | Reiterated Rating | Evercore ISI | Buy | $145.00 |
2016-03-02 | Boost Price Target | Topeka Capital Markets | Buy | $145.00 to $155.00 |
2016-01-31 | Reiterated Rating | Deutsche Bank | Buy | |
2016-01-31 | Reiterated Rating | BTIG Research | Neutral | |
2016-01-31 | Reiterated Rating | Deutsche Bank AG | Buy | |
2016-01-29 | Lower Price Target | Stifel Nicolaus | $158.00 to $150.00 | |
2016-01-29 | Lower Price Target | Mizuho | Buy | $150.00 |
2016-01-29 | Lower Price Target | Leerink Swann | Outperform | $149.00 to $141.00 |
2016-01-29 | Lower Price Target | KeyBanc | Overweight | $152.00 to $150.00 |
2016-01-29 | Lower Price Target | Deutsche Bank | $160.00 to $152.00 | |
2016-01-29 | Lower Price Target | Barclays | Overweight | $165.00 to $160.00 |
2016-01-29 | Lower Price Target | KeyCorp | Overweight | $152.00 to $150.00 |
2016-01-29 | Lower Price Target | Barclays PLC | Overweight | $165.00 to $160.00 |
2016-01-13 | Reiterated Rating | BTIG Research | Neutral | |
2016-01-11 | Boost Price Target | Stifel Nicolaus | Buy | $150.00 to $158.00 |
2016-01-07 | Boost Price Target | Cowen and Company | $160.00 | |
2016-01-06 | Initiated Coverage | Deutsche Bank | Buy | $160.00 |
2016-01-06 | Initiated Coverage | Avondale Partners | Outperform | $168.00 |
2015-12-08 | Upgrade | Goldman Sachs | Buy to Conviction-Buy | $146.00 to $158.00 |
2015-11-24 | Lower Price Target | Goldman Sachs | Buy | $148.00 to $146.00 |
2015-10-22 | Reiterated Rating | BTIG Research | Neutral | |
2015-10-15 | Lower Price Target | Citigroup Inc. | Buy | $152.00 to $149.00 |
2015-10-06 | Initiated Coverage | Argus | Buy | $145.00 |
2015-10-02 | Lower Price Target | Cowen and Company | $150.00 to $140.00 | |
2015-07-23 | Boost Price Target | Leerink Swann | Outperform | $141.00 to $149.00 |
2015-07-23 | Boost Price Target | Robert W. Baird | Outperform | $148.00 to $160.00 |
2015-07-23 | Boost Price Target | Mizuho | Buy | $150.00 to $160.00 |
2015-07-02 | Reiterated Rating | Barclays | Overweight | $165.00 |
2015-05-21 | Reiterated Rating | Jefferies Group | Buy | $150.00 to $155.00 |
2015-05-21 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $145.00 to $150.00 |
2015-05-21 | Boost Price Target | Barclays | Overweight | $160.00 to $165.00 |
2015-04-23 | Set Price Target | Cantor Fitzgerald | Buy | $148.00 |
2015-04-23 | Reiterated Rating | BTIG Research | Neutral | |
2015-01-30 | Reiterated Rating | Cantor Fitzgerald | Buy | $148.00 |
2015-01-30 | Reiterated Rating | BTIG Research | Neutral | |
2015-01-21 | Boost Price Target | Robert W. Baird | Outperform | $142.00 to $144.00 |
2015-01-07 | Initiated Coverage | Barclays | Overweight | |
2014-12-16 | Initiated Coverage | KeyBanc | Buy | $144.00 |
2014-10-23 | Reiterated Rating | Stifel Nicolaus | Buy | $150.00 to $140.00 |
2014-10-03 | Initiated Coverage | ING Group | Neutral | $110.00 to $130.00 |
2014-10-02 | Initiated Coverage | BTIG Research | Neutral | |
2014-09-08 | Initiated Coverage | Morgan Stanley | Overweight | $146.00 |
2014-08-11 | Initiated Coverage | Stifel Nicolaus | Buy | $150.00 |
2014-07-24 | Reiterated Rating | Macquarie | Outperform | $130.00 to $135.00 |
2014-07-17 | Initiated Coverage | Citigroup Inc. | Buy | |
2014-05-22 | Lower Price Target | Leerink Swann | $139.00 to $133.00 | |
2014-05-22 | Boost Price Target | Cowen and Company | $125.00 to $135.00 | |
2014-04-28 | Upgrade | Ned Davis Research | Sell to Neutral | |
2014-04-11 | Reiterated Rating | Goldman Sachs | Buy | $153.00 to $151.00 |
2014-03-21 | Boost Price Target | Bank of America | Buy | $142.00 |
2014-03-21 | Upgrade | Goldman Sachs | Buy | $128.00 to $142.00 |
2014-02-20 | Upgrade | Goldman Sachs | Neutral to Buy | $114.00 to $153.00 |
2014-02-11 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $135.00 |
2014-01-31 | Boost Price Target | Leerink Swann | Outperform | $107.00 to $130.00 |
2014-01-31 | Boost Price Target | Cantor Fitzgerald | $128.00 to $136.00 | |
2014-01-30 | Reiterated | ISI Group | Buy | $121.50 to $130 |
2014-01-30 | Boost Price Target | Evercore ISI | Buy | $121.50 to $130.00 |
2014-01-30 | Boost Price Target | Mizuho | Buy | $130.00 to $140.00 |
2014-01-06 | Reiterated | ISI Group | Buy | $111 to $121.50 |
2014-01-06 | Reiterated Rating | Morgan Stanley | Overweight | $119.00 to $128.00 |
2014-01-06 | Boost Price Target | Evercore ISI | Buy | $111.00 to $121.50 |
2013-10-24 | Boost Price Target | Jefferies Group | Buy | $102.00 to $110.00 |
2013-10-24 | Boost Price Target | Cantor Fitzgerald | $100.00 to $112.00 | |
2013-09-27 | Boost Price Target | Goldman Sachs | Neutral | $89.00 to $94.00 |
2013-09-10 | Reiterated | Mizuho | Buy | $100 to $110 |
2013-07-25 | Reiterated | Cantor Fitzgerald | Buy | $96 to $100 |
2013-05-23 | Reiterated | Cantor Fitzgerald | Buy | $90 to $96 |
2013-04-24 | Reiterated | ISI Group | Buy | $90 to $92.50 |
2013-04-16 | Upgrade | Mizuho | Neutral to Buy | $80 to $90 |
2013-04-15 | Reiterated | Mizuho | Neutral | $65 to $85 |
2013-04-04 | Downgrade | WallachBeth | Buy to Hold | $68 to $76 |
2013-01-31 | Reiterated | ISI Group | Buy | $73.50 to $81 |
2016-07-06 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | |
2016-05-29 | Reiterated Rating | Leerink Swann | Buy | |
2016-05-27 | Boost Price Target | Mizuho | Buy | $166.00 to $170.00 |
2016-05-27 | Reiterated Rating | BTIG Research | Neutral | |
2016-05-19 | Reiterated Rating | Morgan Stanley | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In TMO 1304 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 32.17M |
BlackRock Inc. | 30.69M |
STATE STREET CORP | 16.16M |
Capital World Investors | 13.49M |
FMR LLC | 10.97M |
BlackRock Institutional Trust Company, N.A. | 10.61M |
MORGAN STANLEY | 9.97M |
PRICE T ROWE ASSOCIATES INC /MD/ | 8.96M |
Capital Research Global Investors | 8.76M |
GEODE CAPITAL MANAGEMENT, LLC | 6.76M |
BlackRock Fund Advisors | 6.03M |
BANK OF AMERICA CORP /DE/ | 5.91M |
JPMORGAN CHASE & CO | 5.54M |
NORTHERN TRUST CORP | 3.96M |
PRIMECAP MANAGEMENT CO/CA/ | 3.80M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
CASPER MARC N Chief Executive Officer | 0.07% (294621) | TMO / USB / ZMH / |
Stevenson Mark Executive Vice President | 0.02% (82022) | LIFE / TMO / |
Pesicka Edward A Senior Vice President | 0.02% (80641) | TMO / |
SPERLING SCOTT M | 0.02% (73164) | MSG / TMO / |
WILVER PETER M Sr. VP & CFO | 0.02% (62517) | AQUA / CIR / THC / TMO / |
Thomson Andrew J Senior Vice President | 0.01% (52389) | TMO / |
Lagarde Michel Senior Vice President | 0.01% (48342) | PTHN / TMO / |
Malus Alan J Executive Vice President | 0.01% (47286) | TMO / |
MANZI JIM P | 0.01% (39757) | TMO / |
Williamson Stephen Sr. VP and CFO | 0.01% (39465) | IFF / TMO / |
Loewald Thomas W Senior Vice President | 0.01% (38133) | HBIO / TMO / |
Durbin Patrick M Senior Vice President | 0.01% (36677) | TMO / |
Herrema Gregory J. Senior Vice President | 0.01% (36435) | TMO / |
HOOGASIAN SETH H Sr. VP, Gen. Counsel & Sec. | 0.01% (26530) | TMO / |
Shine Daniel P Senior Vice President | 0.01% (20682) | TMO / |